Drug errors (FDA update)

The US Food and Drug Administration has updated its list of medicines which have had problems in relation to safety and labeling. The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections: Aceon (Perindopril Erbumine) Altace (Ramipril) Atacand (Candesartan Cilexetil) Sporanox (Itraconazole) Zortress (Everolimus) Advicor (Niacin Extended-release/Lovastatin) Altoprev (Lovastatin Extended-release) Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide) Premarin (Conjugated Estrogens,USP) Tekamlo (Aliskiren and Amlodipine) Tekturna (Aliskiren) Tekturna HCT (Aliskiren and Hydrochlorothiazide) Vagifem (Estradiol) Valturna (Aliskiren and Valsartan) Viracept (nelfinavir mesylate) Beyaz (Drospirenone and Ethinyl Estradiol and Levomefolate Calcium) Cimzia (Certolizumab Pegol) Krystexxa (Pegloticase) Levaquin (Levofloxacin) Levemir (Insulin Detemir [rDNA origin]) Neupro (Rotigotine) Nutropin (Somatropin [rDNA origin]) Prandimet (Repaglinide and Metformin HCL) Safyral (Drospirenone and Ethinyl Estradiol and Levomefolate Calcium) Sutent (Sunitinib Malate) Synagis (palivizumab) Tarceva (Erlotinib) Victoza (liraglutide [rDNA]) Votrient (Pazopanib) Xgeva (Denosumab) Yasmin (Drospirenone and Ethinyl Estradiol) Yaz (Drospirinenone and Ethinyl Estradiol) Zegerid (Omeprazole and Sodium Bicarbonate) To read more, see FDA Medwatch